Ultrasound delivery of a TrkA agonist confers neuroprotection to Alzheimer-associated pathologies

Kristiana Xhima,1,2 Kelly Markham-Coultes,1 Rikke Hahn Kofoed,1 H. Uri Saragovi,3,4,5 Kullervo Hynynen6,7 and Isabelle Aubert1,2

Early degeneration of basal forebrain cholinergic neurons contributes substantially to cognitive decline in Alzheimer’s disease. Evidence from preclinical models of neuronal injury and aging support a pivotal role for nerve growth factor (NGF) in neuroprotection, resilience, and cognitive function. However, whether NGF can provide therapeutic benefit in the presence of Alzheimer’s disease-related pathologies still unresolved. Perturbations in the NGF signalling system in Alzheimer’s disease may render neurons unable to benefit from NGF administration. Additionally, challenges related to brain delivery remain for clinical translation of NGF-based therapies in Alzheimer’s disease. To be safe and efficient, NGF-related agents should stimulate the NGF receptor, tropomyosin receptor kinase A (TrkA), avoid activation through the p75 neurotrophin receptor (p75NTR), and be delivered non-invasively to targeted brain areas using real-time monitoring. We addressed these limitations using MRI-guided focused ultrasound (MRigFUS) to increase blood–brain barrier permeability locally and transiently, allowing an intravenously administered TrkA agonist that does not activate p75NTR, termed D3, to enter targeted brain areas. Here, we report the therapeutic potential of selective TrkA activation in a transgenic mouse model that recapitulates numerous Alzheimer’s disease-associated pathologies. Repeated MRigFUS-mediated delivery of D3 (D3/FUS) improved cognitive function in the TgCRND8 model of Alzheimer’s disease. Mechanistically, D3/FUS treatment effectively attenuated cholinergic degeneration and promoted functional recovery. D3/FUS treatment also resulted in widespread reduction of brain amyloid pathology and dystrophic neurites surrounding amyloid plaques. Furthermore, D3/FUS markedly enhanced hippocampal neurogenesis in TgCRND8 mice, implicating TrkA agonism as a novel therapeutic target to promote neurogenesis in the context of Alzheimer’s disease-related pathology. Thus, this study provides evidence that selective TrkA agonism confers neuroprotection to effectively counteract Alzheimer’s disease-related vulnerability. Recent clinical trials demonstrate that non-invasive blood–brain barrier modulation using MRigFUS is safe, feasible and reversible in Alzheimer’s disease patients. TrkA receptor agonists coupled with MRigFUS delivery constitute a promising disease-modifying strategy to foster brain health and counteract cognitive decline in Alzheimer’s disease.
Introduction

The vulnerability of basal forebrain cholinergic neurons (BFCNs) contributes to cognitive dysfunction in individuals with Alzheimer’s disease. Acetylcholinesterase (AChE) inhibitors, which prevent acetylcholine (ACH) breakdown in the synaptic cleft, are currently approved as symptomatic therapies for Alzheimer’s disease and their long-term use may also have disease-modifying benefits. Eventually, however, the underlying cholinergic neurodegeneration becomes severe, and efforts to bolster ACh levels at the synaptic cleft can no longer mask degeneration. In this regard, nerve growth factor (NGF), essential for BFCN survival, function and plasticity, is being pursued as a therapeutic agent for Alzheimer’s disease. NGF has the potential to prevent cholinergic degeneration, stimulate ACh synthesis and release from remaining neurons, and thus could have a significant impact on the clinical progression of Alzheimer’s disease.

Effective clinical translation of NGF-based therapeutic strategies remains a challenge. To date, NGF-based therapeutics have failed to impact cognition in Alzheimer’s disease clinical trials. However, some patients showed increased cholinergic sprouting and upregulation of phenotypic cholinergic markers, implicating a therapeutic benefit of NGF in patients with Alzheimer’s disease. Clinical efficacy may be limited due to impaired NGF signalling mechanisms in Alzheimer’s disease patients and/or technical constraints related to therapeutic delivery. Specifically, NGF binds to two receptors, tropomyosin receptor kinase A (TrkA) and p75 neurotrophin receptor (p75NTR), known in some circumstances—to mediate opposing biological effects: cell survival and cell death, respectively. Pro-survival TrkA is downregulated in Alzheimer’s disease, which may favour NGF binding to p75NTR and ultimately contribute to cholinergic dysfunction. Additionally, in the presence of Alzheimer’s disease pathology, deficits in NGF metabolism could result in the conversion of proNGF to mature NGF, leading to increased extracellular levels of proNGF. ProNGF preferentially interacts with p75NTR to mediate neuronal degeneration. Taken together, these pathways may negate the benefit of TrkA activation by NGF in the Alzheimer’s disease brain. Thus, therapeutics designed to maximize TrkA activation, without engaging p75NTR, may achieve optimal neuroprotection of BFCNs in Alzheimer’s disease.

One such pharmacological agent, D3, is a peptidomimetic agonist of TrkA that promotes neuronal survival, neurite extension and cholinergic tone. However, like NGF, compound D3 does not cross the blood–brain barrier (BBB), which represents a major obstacle for non-invasive delivery to the brain. To date, NGF-related clinical trials have relied on invasive intracranial procedures that carry substantial risk of surgery-related complications, including intracranial haemorrhage and tissue injury. In addition, accurate dosing, spatial targeting and distribution could not be confirmed or controlled following surgical delivery of a gene vector producing NGF or a device encapsulating NGF-secreting cells. Recent post-mortem histological analysis revealed the challenges and importance of accurate stereotactic targeting and the limitation of NGF distribution in Alzheimer’s disease brains. Real-time imaging and monitoring of drug delivery to the brain will be critical for effective clinical application.

To circumvent these translational limitations, we recently established the feasibility of administering intravenous D3 with MRI-guided focused ultrasound (MRIgFUS), to transiently increase BBB permeability in the basal forebrain, thereby delivering D3 to targeted brain areas. This approach led to enhanced cholinergic activity in the TgCRND8 mouse model of amyloidosis. In this study, we aimed to determine whether non-invasive, selective TrkA stimulation is sufficient to impact cognitive decline in the presence of Alzheimer’s disease-related pathology, namely amyloid-β accumulation, cholinergic dysfunction and neurotrophic deficits. We developed a treatment paradigm using MRIgFUS-mediated delivery of D3 that stimulated functional cholinergic innervation to target regions, increased hippocampal neurogenesis, reduced amyloid-β pathology, ultimately converging on improved cognition in a mouse model of amyloidosis that mimics the cholinotrophic deficits seen in Alzheimer’s disease.

Materials and methods

Animals

Sex-balanced, age-matched TgCRND8 mice and non-Tg mice were used in this study. TgCRND8 mice express hAPP695 with the Swedish (KM670/671NL) and Indiana (V717F) mutations under the control of the hamster prion gene promoter. Mice were bred on a hybrid C57BL/6-C3H background. TgCRND8 mice were randomized to experimental groups as follows: (i) D3/FUS-treated (16 mg/kg intravenous D3 and MRIgFUS); (ii) PBS/FUS-treated (intravenous PBS and MRIgFUS); (iii) D3-treated (16 mg/kg intravenous D3, no MRIgFUS); or (iv) PBS-treated (intravenous PBS, no MRIgFUS). Phosphate-buffered saline (PBS)-treated, non-Tg mice were used to control for genotype. Mice were maintained under a 12-h light/dark cycle with free access to food and water. All animal procedures were approved by the Sunnybrook Research Institute Animal Care Committee and conducted in accordance with Canadian Council on Animal Care guidelines. All behavioural, biochemical and histopathological assessments were conducted by investigators blinded to experimental group.

Abbreviations: ACh = acetylcholine; AChE = acetylcholinesterase; BBB = blood–brain barrier; BFCN = basal forebrain cholinergic neuron; ChAT = choline acetyltransferase; MRIgFUS = MRI-guided focused ultrasound; MS/DBB = medial septum/diagonal band of Broca; NBM = nucleus basalis; NGF = nerve growth factor; p75NTR = p75 neurotrophin receptor; TrkA = tropomyosin receptor kinase A

Keywords: tropomyosin receptor kinase A; focused ultrasound; drug delivery; basal forebrain cholinergic neurons; Alzheimer’s disease

Correspondence to: Isabelle Aubert
Sunnybrook Research Institute
2075 Bayview Avenue, Rm. S112
Toronto, ON, M4N 3M5, Canada
E-mail: isabelle.aubert@sri.utoronto.ca; isabelle.aubert@utoronto.ca
TrkA ligand

The selective TrkA ligand D3 (MedChemExpress, HY-17622) was analysed for purity with HPLC (> 98% pure) prior to use in this study. A detailed pharmacological characterization is provided in Maliartchouk et al.18

MRI-guided focused ultrasound

MRigFUS was performed as previously described, using an in-house prototype system (commercialized as LP100, FUS Instruments Inc.).21 Spatial coordinates of the transducer positioning system were co-registered to a 7.0 T MRI (Bruker), allowing FUS targeting from structural MRI. T2-weighed images were used to bilaterally target the basal forebrain in a first sonication, then the hippocampus and cortex in a second sonication. An inter-sonication interval of 5 min allowed microbubbles to be cleared from the circulation. During the first sonication, mice received a tail vein injection of D3 (16 mg/kg) diluted in PBS or PBS only and Definity microbubbles (0.02 ml/kg; Lantheus Medical Imaging). In the second sonication, animals received another dose of Definity and Gadovist (0.2 ml/kg, Bayer). Each injectable was followed by a 150 μl saline flush for transfer into the bloodstream.

Acoustic emissions were recorded using an in-house manufactured PZT hydrophone and coupled to a feedback controller. The applied pressure was increased step-wise after each pulse until the magnitude of subharmonic acoustic emissions passed 3.5 times the mean of baseline. The applied pressure was reduced to 50% and maintained at this level for the rest of the sonication. Peak pressure was calculated for each target and averaged across all targets within an animal.

BBB permeability was confirmed by an increase in Gadovist signal intensity on T1-weighed images obtained 5 min after the second sonication. Percent enhancement was quantified as the mean pixel intensity in a 2 mm × 2 mm voxel region of interest corresponding to each target spot relative to an untreated reference region and averaged across all focal spots within an animal (MATLAB).

Behavioural testing

All behavioural testing was performed during the light phase of the cycle by an experimenter blinded to the treatment. Behavioural procedures are detailed in the Supplementary material.

Biochemical assays for cholinergic function

Mice were anaesthetized, decapitated, and the brains were rapidly dissected on ice. Dissected medial septum/diagonal band of Broca (MS/DBB) and nucleus basalis (NBM) were ash-frozen and stored at −80°C. Choline acetyltransferase (ChAT) activity was measured by incorporation of 14C-acetyl-CoA into 14C-ACh, as previously described.24 Dissected hippocampus and cortex were frozen at −80°C until assayed for AChE activity using the Amplex Red detection kit (Invitrogen). Freshly dissected hippocampus and cortex were separated into 500 μm transverse slices for evaluation of basal and potassium-evoked AChE release.21 Tissue ACh and choline were extracted from freshly dissected hippocampus and cortex as described.24 The final ACh and choline content were determined using the Amplex Red detection kit (Invitrogen). Radioactivity was measured using liquid scintillation counting (Beckman Coulter). Protein content was determined using the bicinchoninic acid assay (Thermo Scientific).

Immunohistochemistry and imaging

Mice were deeply anaesthetized with ketamine/xylazine (CDMV). Animals were intracardially perfused with saline followed by 4% paraformaldehyde. Brains were removed, post-fixed in 4% paraformaldehyde for 24 h at 4°C, then placed in 30% sucrose. Coronal, 40 μm brain sections were prepared using a sliding microtome (Leica) and stored at −20°C in cryoprotectant buffer. Free-floating sections were rinsed with 0.1 M PBS, then incubated in blocking solution (PBS with 0.3% Triton X-100 and 10% donkey serum) for 1 h at room temperature. Sections were incubated for 72 h at 4°C with the following primary antibodies: goat anti-ChAT (1:500; EMD Millipore, AB144P), mouse anti-BrdU (1:400; ExBio, 11-286-C100), rabbit anti-DCX (1:200; Abbcam, ab207175), guinea pig anti-NeuN (1:500; EMD Millipore, ABN90), mouse 6F3D anti-amyloid-β (1:200; Dako, M0872). Brain sections were rinsed with PBS, then incubated with fluorescently conjugated secondary antibodies (1:200; Jackson ImmunoResearch) and DAPI (1:15000; Invitrogen) for 2 h at room temperature. Amyloid plaques were labelled with 1% Thioflavin S for 7 min, followed by two sequential incubations in 70% ethanol for 5 min. For bromodeoxyuridine (BrdU) staining, antigen retrieval was performed by incubating sections in 2 N HCl for 30 min at 37°C. Acid was neutralized in borate buffer (pH 8.5) for 10 min. For doublecortin (DCX) staining, Tris-EDTA buffer (pH 8.0) at 80°C for 40 min was used for antigen retrieval.

Immunofluorescence was visualized with a Nikon A1 laser scanning confocal microscope and images were acquired with NIS-Elements software (Nikon). Z-stack images were acquired with 2, 1 and 0.2 μm optical thickness using the 10×, 20× and 60× objectives, respectively. Quantitative image analyses were performed while blinded to treatment groups.

Statistical analysis

Prism 8 software (GraphPad) was used for statistical analysis. All values are expressed as the means ± standard error of the mean (SEM). Two groups were compared using unpaired Student’s t-tests. For analysis of unshredded nest material between groups, we used the Kruskal-Wallis test with the Dunn post hoc method. The following outcome measures were analysed using repeated measures two-way ANOVA: nesting score, Barnes Maze learning and search strategy score, contrast enhancement, peak pressure during sonication and body weight. ChAT+ fibre density, DCX+ Sholl crossings and plaque distribution analysis were assessed by two-way ANOVA. All other parameters were analysed using a one-way ANOVA. The Holm-Sidak post hoc test was used for multiple comparisons in statistically significant ANOVAs. Correlation was performed using linear regression analysis with 95% confidence intervals. P < 0.05 was set as threshold for statistical significance.

Data availability

Additional data related to this paper are available from the corresponding author upon reasonable request.

Results

MRigFUS-mediated delivery of D3 improves cognition in TgCRND8 mice

The TgCRND8 model is an aggressive, early-onset model of amyloidosis. Significant amyloid-β plaque pathology and cognitive deficits emerge by 3 months.23 Regional progression of plaque
pathology is similar to that seen in Alzheimer’s disease, beginning in the cerebral and spreading to the hippocampus, olfactory bulbs, and thalamus by 4 months. Aberrant amyloid-β accumulation induces cortical and hippocampal synaptic loss, neuronal network dysfunction and degeneration. Functional cholinergic deficits are also apparent in TgCRND8 mice by 4 months. Aberrant amyloid deposition, cholinergic degeneration and neurogenesis deficits, are already well established.

We first examined whether selective TrkA stimulation with D3, combined with MRTg/FUS delivery, could promote cognitive function. Mice at 5 months of age were treated once per week for three consecutive weeks, followed by behavioural testing (Fig. 1A–D). Nest building was improved by D3/FUS treatment relative to PBS/FUS and D3-treated controls (Fig. 1E and Supplementary Fig. 2A). D3/FUS-treated TgCRND8 mice also shredded more nesting material than PBS/FUS and D3-treated TgCRND8 mice, comparable to non-Tg mice (Supplementary Fig. 2B). Nest building behaviour of TgCRND8 mice prior to the first treatment was balanced after treatment groups were randomized (Supplementary Fig. 2C and D).

In the novel object recognition test, D3-treated TgCRND8 demonstrated impaired recognition memory, without preferential exploration of a novel object over a familiar one (Fig. 1F and Supplementary Fig. 3A). D3/FUS-treated mice performed better than D3 and PBS/FUS-treated mice in demonstrating their preference for the novel object, comparable to non-Tg controls (Fig. 1F and Supplementary Fig. 3B). Novelty-seeking behaviour as measured by total object exploration time was unaffected by treatment (Fig. 1G and Supplementary Fig. 3C). No differences in locomotor behaviour were observed across groups (Supplementary Fig. 3D and E).

In the Y maze, spontaneous alternation was used as an index of spatial working memory. The performance of D3/FUS-treated mice was comparable to non-Tg littermates and significantly better than D3 and PBS/FUS-treated TgCRND8 mice (Fig. 1H). Exploratory activity assessed by search density (Supplementary Fig. 4A) and total entries into the arms did not differ between groups (Fig. 1I). No differences in average velocity and distance travelled were observed across treatments (Supplementary Fig. 4B and C). Prior to the first treatment, TgCRND8 mice allocated to different experimental conditions demonstrated similar performance in Y maze alternation (Supplementary Fig. 4D–G).

Mice from all groups were able to learn the location of an escape box in the Barnes maze over a 4-day training period (Fig. 1A). However, the performance of D3-treated TgCRND8 mice was worse compared to non-Tg mice in the acquisition phase, indicating a genotype deficit in learning this task (Fig. 2A). Distance travelled followed a similar trend as latency to escape (Supplementary Fig. 5A). Motor performance was unaffected across trials (Supplementary Fig. 5B). Spatial search strategies were classified (Fig. 2B) and assigned a relative score based on spatial learning (Fig. 2C). Non-Tg mice shifted from random and serial navigation on Day 1 towards more efficient, spatial navigation on Day 4 (Fig. 2C and D). In contrast, D3-treated TgCRND8 mice relied mostly on random and serial navigation over all trial days (Fig. 2C and D). On Day 5, the escape box was removed to test memory recall (Fig. 2E–H). D3-treated TgCRND8 mice spent less time in the target zone than non-Tg mice (Fig. 2F) and exhibited a higher number of errors (i.e. the number of entries to a non-target hole) (Fig. 2G and Supplementary Fig. 5C and D). Analysis of navigation strategy in the probe trial indicated that D3-treated TgCRND8 mice used less spatially-dependent strategies than non-Tg mice (Fig. 2A–D) and bias for the target zone in the probe trial (Fig. 2E–H). No effect of FUS alone was observed (Fig. 2A–H). Mice were subsequently trained in a reversal learning paradigm. D3-treated TgCRND8 mice demonstrated impaired reversal learning (Fig. 2I) and lower mean spatial navigation scores compared to non-Tg mice (Fig. 2J). Unlike non-Tg mice, D3-treated TgCRND8 mice adopted predominantly random and serial search strategies (Fig. 2K). Distance travelled followed a similar trend as latency to escape (Supplementary Fig. 6A). No differences were observed in mean speed during reversal learning across treatment groups, ruling out a priori differences in locomotor activity (Supplementary Fig. 6B). During the reversal probe trial, TgCRND8 mice spent less time in the target zone than non-Tg mice (Fig. 2L and Supplementary Fig. 6C) and relied on non-spatial navigation (Fig. 2M). There was an increase in number of errors made by D3-treated TgCRND8 mice relative to non-Tg controls (Supplementary Fig. 6D–F). D3/FUS-treated mice showed improvement in reversal learning performance indicating that cognitive flexibility is restored (Fig. 2I–M). Altogether, these findings indicate that repeated D3/FUS, relative to D3 and PBS/FUS treatments, led to improved performance in cognitive tasks. It is important to note that D3/FUS enhanced cognitive function in the context of mid-stage amyloid pathology and Alzheimer’s disease-related neurotrophic deficits, further supporting the translational potential of this work.

D3/FUS rescues BFCNs and associated pathways in TgCRND8 mice

Next, we sought to evaluate the potential neural mechanisms underlying improved cognitive function following D3/FUS treatment. To examine the structure and function of BFCNs, the MS/DBB and NBM subregions of the basal forebrain were immunostained for ChAT, the enzyme responsible for ACh synthesis (Fig. 3A). In both the MS/DBB and NBM, no difference in the numbers of ChAT+ cells were detected across experimental conditions (Fig. 3B). However, D3/FUS-treated TgCRND8 mice exhibited an increase in the ChAT+ soma size (Fig. 3C), extension (Fig. 3D), surface area (Fig. 3E) and branching (Fig. 3F) of ChAT+ neurites, relative to PBS, D3 and FUS-treated mice. D3/FUS also increased ChAT enzyme activity in the MS/DBB and NBM of TgCRND8 mice, relative to D3 and PBS/FUS alone (Fig. 3G).

To determine whether changes in the BFCN soma were accompanied by changes in their terminal fields, we examined ChAT+ fibres in the hippocampus and cortex (Fig. 4). Non-Tg mice exhibited an extensive network of cholinergic fibres in the hippocampus.
and cortex, with regional differences in fibre densities (Fig. 4A and Supplementary Figs 7 and 8). In the CA1 and CA3 subfields of the hippocampus, the most notable loss of fibres in TgCRND8 mice appeared in the stratum radiatum and stratum lacunosum-moleculare (Fig. 4A and Supplementary Fig. 7). In the dentate gyrus, decreased fibre innervation was most prominent in the molecular layer (Supplementary Fig. 7). TgCRND8 mice also displayed a significant decrease of ChAT+ fibre density in the frontal (Fig. 4A), parietal and entorhinal (Supplementary Fig. 8) cortices, which were increased following D3/FUS treatment. Overall, these findings demonstrate that TrkA stimulation is sufficient to rescue the degeneration and maintain the phenotype of BFCNs in TgCRND8 mice.

D3/FUS promotes cholinergic function in TgCRND8 mice

Next, we investigated whether anatomical changes at the level of the soma and terminal networks, as well as the functional upregulation of ChAT activity, led to enhanced cholinergic tone as measured by basal and potassium-induced ACh release in hippocampal and cortical slices (Fig. 4B). Potassium depolarization increased the release of $^{14}$C-ACh from brain slices. Potassium-induced ACh release was higher in D3/FUS treated slices compared to D3 or PBS/FUS-treated slices (Fig. 4B), suggesting that cholinergic tone was enhanced following D3/FUS in TgCRND8 mice. Regional analysis of evoked ACh release revealed similar trends in the hippocampus and several cortical areas (Fig. 4B). Consistent with increased ChAT activity (Fig. 3G), the levels of hippocampal and cortical tissue ACh content were significantly higher in D3/FUS-treated TgCRND8 compared to D3 and PBS/FUS-treated controls (Fig. 4C). Moreover, increased hippocampal and cortical AChE enzymatic activities were observed in D3/FUS-treated animals (Fig. 4D). Together, these findings demonstrate increased hippocampal and cortical cholinergic function as a result of D3/FUS treatment. Adequate levels of ACh synthesis and release serve to maintain cholinergic neurotransmission required for cognitive function.

D3/FUS stimulates hippocampal neurogenesis in TgCRND8 mice

The innervation of the hippocampus by medial septum cholinergic neurons promotes the proliferation and survival of hippocampal neural progenitor cells. Newborn neurons of the dentate gyrus
continuously integrate into the hippocampal circuitry, contributing to learning and memory. Thus, we evaluated hippocampal neurogenesis as another potential contributor to behavioural improvement following D3/FUS treatment.

To evaluate proliferative activity in the dentate gyrus, mice were injected with the thymidine analogue BrdU, 3, 4 and 5 days after the last treatment (Fig. 5A). Twenty-four hours later, BrdU incorporation was quantified in the dentate gyrus (Fig. 5A and B). D3/FUS increased the total number of BrdU+ cells in TgCRND8 mice relative to PBS/FUS, D3 and PBS-treated controls (Fig. 5C). To evaluate the proportion of proliferating cells that differentiated into neurons, cells in the dentate gyrus were also analysed for co-expression of BrdU and the immature neuronal marker, DCX (Fig. 5D). Consistent with previous reports in TgCRND8 mice, there were fewer BrdU+/DCX+ cells in TgCRND8 mice relative to PBS/FUS and D3-treated controls (Fig. 5D). It is worth noting that FUS alone also increased newborn neuron proliferation as previously reported, but to a lesser extent than D3/FUS (Fig. 5D). Newborn neurons are known to migrate into the granule cell layer during the first 4 weeks prior to functional integration into pre-existing circuits. Here, the relative proportion of BrdU+ cells in

Figure 2 MRIgFUS-mediated delivery of D3 promotes spatial memory and cognitive flexibility in TgCRND8 mice. In the Barnes maze, D3/FUS enhanced spatial navigation in TgCRND8 mice relative to PBS/FUS and D3-treated TgCRND8 controls. (A) TgCRND8 mice demonstrated a slower learning curve relative to non-Tg mice, unless treated with D3/FUS. (B) Search strategies used by mice in the Barnes maze were classified. (C and D) Similar to non-Tg controls, D3/FUS-treated TgCRND8 mice used spatially-dependent search strategies to locate the escape box. (E-H) Performance in the probe test was improved by D3/FUS treatment, reflecting memory retention. This was demonstrated by (E) higher search density at the previous location of the escape box, (F) more time spent near the target hole in the absence of the escape box, (G) fewer entries in non-target holes (errors) and (H) higher search strategy scores of D3/FUS-treated TgCRND8 mice relative to PBS/FUS and D3-treated controls. (I-K) Barnes maze reversal learning, with the target hole re-located 180° from the original position, was improved by D3/FUS treatment in TgCRND8 mice. (J) Relative to PBS/FUS and D3-treated TgCRND8 mice, non-Tg mice and D3/FUS-treated TgCRND8 mice demonstrated faster escape latency, (J) better spatially-dependent navigation as demonstrated by higher search strategy scores and (K) percentage of spatial strategies used across trial days. (L and M) Performance in the reversal probe test was improved in TgCRND8 mice following D3/FUS treatment, with (L) more time spent in the target zone and (M) higher search strategy score relative to D3-treated TgCRND8 mice. Statistics: (A, C, I and J) Repeated measures and (F–H, L and M) one-way ANOVA with Holm-Sidak post hoc test. Significance: *p<0.05; **p<0.01; ***p<0.001. †Comparison of D3-treated TgCRND8 mice with PBS-treated non-Tg mice (genotype effect). ††Comparison of PBS/FUS-treated with D3/FUS-treated TgCRND8 mice (D3 effect). †††Comparison of D3-treated with D3/FUS-treated TgCRND8 mice (D3/FUS effect). Data represent means ± SEM; n = 10–12 per group.
Figure 3 Repeated MRigFUS delivery of D3 improves basal forebrain cholinergic neuron structural integrity and function in TgCRND8 mice. (A) Representative confocal images from non-Tg PBS, TgCRND8 PBS, PBS/FUS, D3 or D3/FUS-treated mice, show ChAT+ neurons in the MS/DBB and NBM. (B) Relative to non-TgCRND8, all groups of TgCRND8 mice had a comparable number of ChAT+ BFCNs. (C) Soma size, (D) mean neurite length, (E) total surface area and (F) branching complexity were decreased in ChAT+ BFCNs of PBS-treated TgCRND8 mice compared to non-Tg littermates, and increased with D3/FUS treatment. (G) ChAT enzyme activity was enhanced by D3/FUS in TgCRND8 mice and comparable to non-Tg levels. Scale bars in A = 100 μm; i–v = 30 μm. Statistics: one-way ANOVA with Holm-Sidak post hoc test. Significance: *,+,*+,*++,*+++ P < 0.05; **,**+,**,+++ P < 0.01; ***,**+,**,+++,**,+++ P < 0.001. †Comparison of PBS-treated TgCRND8 mice with PBS-treated non-Tg mice (genotype effect). +Comparison of PBS/FUS-treated with D3/FUS-treated TgCRND8 mice (D3 effect). *Comparison of PBS and D3-treated TgCRND8 mice with D3/FUS-treated TgCRND8 mice as shown (D3/FUS effect). Data represent means ± SEM; n = 4–6 per group.
Figure 4 MRIgFUS-mediated delivery of D3 enhances cholinergic function in hippocampal and cortical areas. (A) Representative confocal images from non-Tg PBS, TgCRND8 PBS, PBS/FUS, D3 or D3/FUS-treated mice at 6.5 months of age show ChAT+ fibres in the hippocampus and prefrontal cortex. A decrease in ChAT+ fibre density in CA1 subfield of the hippocampus was apparent in PBS-treated TgCRND8 mice relative to non-Tg mice.

(Continued)
the inner, mid and outer third of the granule cell layer were reduced in TgCRND8 compared to non-Tg mice; this shift was normalized following D3/FUS, but not PBS/FUS or D3 treatment (Fig. 5E).

To evaluate the survival of newborn neurons in the dentate gyrus, BrdU+ cells and the proportion of BrdU+ cells expressing the mature neuronal marker, neuronal nuclei (NeuN), were counted 4 weeks later (Fig. 5A and F). A decrease in the total number of surviving BrdU+ cells (Fig. 5G) and a lower percentage of BrdU+/NeuN+ cells (Fig. 5H) were observed in TgCRND8 mice relative to non-Tg controls; this deficit was rescued in D3/FUS-treated mice, but not PBS/FUS or D3-treated mice. A similar trend was observed in the migration of BrdU+/NeuN+ cells (Fig. 5I), indicating that only D3/FUS treatment facilitates migration of newborn neurons in the dentate gyrus. Overall, these findings suggest that MRigFUS delivery of D3 stimulates hippocampal neurogenesis in the presence of amyloid-β-driven deficits.

To track morphological changes of newborn neurons, DCX+ cells in the dentate gyrus were analysed 6 days after the last sonication (Fig. 6A). In the healthy adult dentate gyrus, dendritic processes of newborn neurons extend through the granule cell layer with minimal branching and extensive arborization in the molecular layer.36 We found that the total dendrite length (Fig. 6B) and apical dendrite length (Fig. 6C) of DCX+ cells were reduced in TgCRND8 mice and normalized in D3/FUS-treated mice. Sholl crossings of DCX+ fibres were used to evaluate dendritic branching complexity of newborn neurons.30 TgCRND8 mice presented with decreased dendritic complexity compared with non-Tg controls, which was increased by D3/FUS (Fig. 6D). Consistent with previous findings,40 FUS alone also enhanced newborn neuron complexity in TgCRND8 mice, but to a much lesser degree than D3/FUS (Fig. 6A–D). Linear regression analysis revealed a positive correlation between total dendritic length and ChAT+ fibre density in subregions of the dentate gyrus (Fig. 6E–G), implicating a role for cholinergic-mediated control of dendritic complexity. Together, the morphological analyses of DCX+ fibres revealed that neurons produced as a consequence of D3/FUS treatment developed a morphology that is likely to establish afferent connections, and thus may play a functional role in hippocampus-mediated cognition.

Reduced amyloid pathology after MRigFUS delivery of D3

We next examined amyloid pathology in 6.5-month-old TgCRND8 mice, 4 weeks after the last treatment. Immunostaining with the amyloid-β antibody 6F3D revealed a robust decrease of hippocampal (Fig. 7A–F) and cortical (Fig. 7G–L) plaque load following D3/FUS. There was a reduction in the total surface area covered by plaques (hippocampus: 16.6 ± 4.0%; cortex: 17.5 ± 5.3%), number of plaques (hippocampus: 27.9 ± 5.0%; cortex: 31.7 ± 5.1%) and mean plaque size (hippocampus: 29.1 ± 7.2%; cortex: 35.4% ± 5.2%) in D3/FUS-treated animals relative to PBS, D3 and PBS/FUS-treated controls. In 6.5-month-old TgCRND8 mice with significant amyloid-β burden, there was no reduction in plaque surface area, number of plaques or mean plaque size in PBS/FUS-treated mice. Plaque density data were also analysed by plaque size (Fig. 7E and K). Plaques of all sizes were reduced following D3/FUS (hippocampus: Fig. 7E and F; cortex: Fig. 7K and L). The proportion of plaques larger than 2000 μm² were decreased in PBS/FUS and D3/FUS-treated mice (hippocampus: Fig. 7F; cortex: Fig. 7L).

We also evaluated dystrophic cholinergic fibres in the vicinity of amyloid plaques found in the hippocampus and cortex (Fig. 7M–S). Dystrophic ChAT+ neurites were observed in the cortex and hippocampus of TgCRND8 mice (Fig. 7M). D3/FUS reduced the total area covered by ChAT+ dystrophic neurites in TgCRND8 mice, with fewer ChAT+ clusters, but the same area per cluster (hippocampus: Fig. 7N–P; cortex: Fig. 7Q–S). Thus, the decrease in amyloid-β deposition in D3/FUS-treated TgCRND8 mice may have contributed to the reduction in ChAT neurite dystrophy.

**Figure 4 Continued**

A decrease in cholinergic innervation was also found across cortical layers in PBS-treated TgCRND8 mice compared to non-Tg controls. D3/FUS treatment increased cholinergic innervation throughout the prefrontal cortex and CA1. (B–D) D3/FUS promoted (B) basal and depolarization-induced ACh release from hippocampal and cortical slices. (C) tissue ACh content in the hippocampus and cortex and (D) AChE activity in these regions. Scale bar in A = 50 μm. Statistics: (B) two-way or (C and D) one-way ANOVA with Holm-Sidak post hoc test. Significance: ††††P < 0.0001; **+††††P < 0.001; ††††††††††P < 0.0001; †Comparison with basal ACh release of the same treatment group (depolarization effect). ††Comparison of D3-treated TgCRND8 mice with PBS-treated non-Tg mice (genotype effect). †††Comparison of PBS/FUS-treated with D3/FUS-treated TgCRND8 mice (D3 effect). ††††Comparison of D3-treated TgCRND8 mice with D3/FUS-treated TgCRND8 mice (D3/FUS effect). Data represent means ± SEM; n = 6 per group. or = stratum oriens; pyr = stratum pyramidale; rad = stratum radiatum; lm = stratum lacunosum moleculare.

**Discussion**

Our results revealed that MRigFUS-mediated delivery of a TrkA ligand enhanced cognition in TgCRND8 mice via several mechanisms, including improvements in the septohippocampal and basolacocortical cholinergic pathways—anatomically and functionally, increased hippocampal neurogenesis and reduced brain amyloid-β burden. These findings are consistent with our previous investigation where a TrkA ligand improved memory function, anxiety-related activity and body weight in TgCRND8 mice. 

**MRigFUS-BBB permeabilization combined with D3 is well tolerated**

Increased BBB permeability was achieved at MRigFUS-targeted sites and was comparable across weekly treatments (Fig. 8A–C). Specifically, there was no difference in the mean contrast enhancement between PBS/FUS-treated (28.7 ± 1.9%) and D3/FUS-treated mice (29.4 ± 1.7%) (Fig. 8B). Similarly, no significant difference in sonication pressure sustained after a threshold event was detected (PBS/FUS: 0.681 ± 0.044 MPa; D3/FUS: 0.719 ± 0.041 MPa; Fig. 8C). Overall, these findings suggest that consistent BBB permeabilization was achieved across treatment conditions and upon repeated FUS application.

Previous findings indicate that systemic or intracerebroventricular NGF infusion can lead to side effects such as weight loss, Schwann cell hyperplasia and aberrant sensory and sympathetic sprouting.43,44 Thus, adverse effects must be carefully considered for potential clinical translation. Motor behaviour was assessed in the open field for 10 min; total distance travelled and average velocity were similar across treatment groups (Fig. 8D–F). Anxiety-like behaviour in the open field test was also unaffected across experimental conditions (Fig. 8G and H). Mice across treatment groups displayed comparable performance in the marble burying test for anxiety-related activity (Fig. 8I and J). With respect to body weight, TgCRND8 mice weighed less than non-Tg mice (Fig. 8K), as expected for the stage of disease progression.45 Average body weight did not differ among D3, PBS/FUS or D3/FUS groups (Fig. 8K). Together, these findings suggest that FUS, D3 and combined D3/FUS exposure do not negatively impact motor function, anxiety-like behaviour or body weight.
burden. D3/FUS treatment in TgCRND8 mice restored performance on tasks related to cognitive domains affected in Alzheimer’s disease, including recognition memory, working memory, spatial learning and reference memory, cognitive flexibility and activities of daily living.46 Administration of D3 or mutant NGF with reduced binding affinity to p75NTR in transgenic models of amyloidosis, either prior to or at the onset of cognitive impairment and amyloid-β deposition, exerted neuroprotective effects, decreased brain amyloid-β levels and prevented memory deficits.12,20,47 To our knowledge, our study represents the first time TrkA-mediated bioeffects have been harnessed to improve cognition in the context of well-established behavioural deficits, amyloid-β plaque pathology and cholinergic dysfunction, similar to a prospective clinical condition.

We demonstrate that selective TrkA stimulation can promote neuronal function in the presence of Alzheimer’s disease-related neurotrophic signalling deficits, which may render native NGF ineffective. The TrkA-specific ligand D3 promoted neuroprotection even in the presence of an imbalance between TrkA and p75NTR expression in TgCRND8 mice,21 similar to Alzheimer’s disease.16 Since TrkA expression is downregulated, native NGF may favour binding to p75NTR over TrkA, leading to deficits in TrkA-mediated signalling and the selective vulnerability of BFCNs.17 In support of this hypothesis, we previously showed that native NGF failed to promote TrkA signalling in TgCRND8 mice.21 Native NGF also failed to restore cognition in hAPP-J20 transgenic mice, although NGF receptor levels remain to be characterized in this Alzheimer’s disease model.20

Figure 5 MRIgFUS BBB modulation combined with D3 delivery increases proliferation and survival of newborn neurons in TgCRND8 mice. (A) Following the last weekly treatment, separate cohorts of mice were injected with BrdU and sacrificed after 6 days and 28 days to label proliferating and surviving cells, respectively. (B) A representative confocal image of a BrdU (red), DCX (green), and DAPI (blue) labelled section 24 h after the last BrdU injection. (C) PBS/FUS-treated and D3/FUS-treated mice had more BrdU+ proliferating cells compared to PBS-treated TgCRND8 controls. (D) TgCRND8 mice had significantly fewer BrdU+ proliferating cells co-labelled with the immature neuronal marker DCX. This deficit was rescued by PBS/FUS and D3/FUS treatments. (E) Neuronal migration, as measured by the distribution of BrdU-labelled cells within the granule cell layer was impaired in TgCRND8 mice, and restored following D3/FUS treatment. (F) A representative confocal image of a BrdU (red) and NeuN (green) labelled section 28 days after the last treatment. (G) There was a significant genotype deficit in the number of surviving BrdU+ cells, (H) BrdU+ cells co-labelled with the mature neuronal marker NeuN, and (I) migration into the granule cell layer, which were increased in D3/FUS-treated mice. Statistics: (C–E, G–I) one-way ANOVA with Holm-Sidak post hoc test. Significance: *P < 0.05; **P < 0.01; ***P < 0.001; ^Comparison of PBS-treated non-Tg mice with PBS-treated TgCRND8 mice (genotype effect); †Comparison of PBS-treated TgCRND8 mice with PBS/FUS-treated TgCRND8 mice (FUS effect); ††Comparison of PBS/FUS-treated with D3/FUS-treated TgCRND8 mice (D3 effect). Data represent means ± SEM; n = 6 per group. oml = outer molecular layer; iml = inner molecular layer; gcl = granule cell layer; sgz = subgranular zone; hil = hilus; igl = inner granule layer; mgl = middle granule layer; ogl = outer granule layer.
One notable mechanism by which cholinergic input from the basal forebrain modulates hippocampal circuitry is neurogenesis. Considerable evidence supports a role for neurogenesis in Alzheimer’s disease. Neurogenesis is impaired by amyloid-β deposition in TgCRND8 mice and other mouse models of Alzheimer’s disease. Alterations in hippocampal neurogenesis have also been described in Alzheimer’s disease patients. Our results suggest that stimulating cholinergic tone, via MRgFUS delivery of D3, can stimulate survival of newborn neurons, which may contribute to improved learning and memory, even in a hostile brain environment with Alzheimer’s disease pathology (Fig. 5). In this context, it is worth noting the role of amyloid-β attenuation on the neurogenic niche; that is, whether amyloid-β reduction following D3/FUS could alone promote neurogenesis, and thereby ameliorate deficits in neurogenesis-related behavioural tasks. Previous work in 7-month-old TgCRND8 mice demonstrated that scyllo-inositol, an amyloid-β anti-aggregation agent that halts its progression, did not impact the proliferation and survival of newborn neurons; whereas combination treatment with neotrofin, a purine derivative that induces BDNF and NGF expression, was sufficient to promote neurogenesis. Neotrofin treatment alone also did not enhance neurogenesis, indicating that amyloid-β indeed negatively regulates neurogenesis in this transgenic model. Overall, these data support a mechanism whereby neurogenesis after D3/FUS treatment is improved by modulating amyloid pathology and neurotrophic support in combination. Thus, sustained TrkA activation in the earliest stages of Alzheimer’s disease pathophysiology may protect hippocampal neurons from death with disease progression. The effects of MRgFUS-mediated TrkA activation extend to potent anti-amyloidogenic actions that may slow cognitive decline. Four weeks after the last D3/FUS treatment, widespread reduction in amyloid plaque pathology and cholinergic dystrophic neurites surrounding plaques were observed in the MRgFUS-targeted cortex and hippocampus (Fig. 7). Our results are consistent with the decreased amyloid-β load in the cortex and hippocampus reported after non-targeted intranasal delivery of an NGF mutant with lower affinity for p75NTR than native NGF (and identical binding to TrkA) over a 21-day period, further supporting the notion of TrkA-mediated modulation of amyloidosis. In contrast, systemic administration of a BBB-permeable p75NTR antagonist, LM11A-31, did not change the total cortical area occupied by plaques, suggesting that NGF/TrkA signalling is responsible for reduced amyloid-β pathology. One potential mechanism by which increased cholinergic tone may be neuroprotective against amyloid-β-induced toxicity is by shifting APP processing towards nonamyloidogenic cleavage. Second, a role for TrkA-mediated...
Figure 7 MRIgFUS-mediated delivery of D3 reduces amyloid plaque deposition and cholinergic dystrophic neurites in the cortex and hippocampus. (A) Representative confocal images from the hippocampus of PBS, PBS/FUS, D3 and D3/FUS-treated TgCRND8 mice stained for amyloid-β (red). (B) Total hippocampal surface area occupied by amyloid-β. (C) Density of plaques and (D) mean plaque size were reduced in D3/FUS-treated mice relative to PBS, PBS/FUS and D3-treated mice. (E) A range of plaque sizes were decreased by D3/FUS treatment relative to PBS-treated controls. (F) The number of large plaques defined by an area >2000 μm² were reduced in PBS/FUS and D3/FUS-treated mice. (G) Representative amyloid-β staining from cortical brain sections. (H) D3/FUS treatment decreased cortical amyloid coverage, (I) density of plaques, and (J) mean plaque size. (K) A range of plaques sizes decreased by D3/FUS treatment relative to PBS-treated controls. (L) PBS/FUS treatment preferentially reduced the number of large plaques. (M) Representative confocal images of ChAT-immunostained dystrophic neurites (green) surrounding plaques labelled with Thioflavin S (red). (N) D3/FUS treatment decreased the total hippocampal area occupied by clusters of dystrophic neurites and (O) number of clusters, (P) but not the (Continued)
ANOVA with Holm-Sidak.

PBS-treated mice with PBS/FUS-treated TgCRND8 mice (FUS effect). +Comparison of PBS/FUS-treated with D3/FUS-treated TgCRND8 mice (D3 effect).

*Comparison of PBS or D3-treated TgCRND8 mice with D3/FUS-treated TgCRND8 mice as shown (D3/FUS effect). Data are presented as mean ± SEM; per group.

may contribute to the overall reduction in amyloid-β clearance by microglia has been proposed.⁵²,⁵³ Third, transient BBB permeability induced by the interaction of ultrasound and microbubbles has been shown to reduce amyloid-β pathology in APP-overexpressing mice,⁴⁰,⁵²,⁵³ albeit by incompletely understood clearance pathways. One underlying mechanism is increased internalization and degradation of amyloid-β by microglia that become activated in response to BBB modulation.⁵²,⁵³ Here, MRIgFUS treatment shifted the distribution of plaque size toward smaller plaques (Fig. 7E and K), with the total plaque area remaining unaffected (Fig. 7B and H). These findings are consistent with clearance of amyloid-β by microglia preventing further plaque growth. However, the reduction in amyloid-β pathology following MRIgFUS alone was not sufficient to improve performance in cognitive tasks (Fig 1). In combination, factors such as cholinergic modulation of APP processing, and amyloid-β clearance by microglia as a result of direct TrkA stimulation and/or FUS-induced BBB permeability, may contribute to the overall reduction in amyloid-β pathology following D3/FUS treatment.

It is important to consider the overall contribution of amyloid-β reduction to neuronal and cognitive improvement. D3 selectively engages TrkA, a receptor widely accepted to be preferentially and highly expressed on cholinergic neurons,⁵¹ supporting the hypothesis that it is trophic support provided to cholinergic neurons that ultimately drives the reduction of amyloid load. This interpretation is also consistent with the potent anti-amyloidogenic effects of cholinergic-related treatment in preclinical models of Alzheimer’s disease.⁵² Positive feedback could occur with amyloid-β reduction representing a means of reinforcing and strengthening cholinergic terminals. However, amyloid-β–directed interventions, including those that entirely halt amyloid-β accumulation, serve to slow down and/or prevent further neuronal degeneration, rather than rescue atrophy as observed in this study. Additionally, while D3/FUS treatment does indeed reduce amyloid plaque load, it does not halt the progression of amyloid-β pathology to baseline levels observed in 5-month-old TgCRND8 mice (Supplementary Fig. 1). Thus, it is unlikely that the lower levels of amyloid-β following D3/FUS is the main effect driving improvements in neuronal structure, function and downstream cognition, matched to non-Tg levels. Emerging evidence in Alzheimer’s disease patients also implicates a role for NGF/TrkA signalling, cholinergic neurotransmission and neurogenesis in neuronal resilience to Alzheimer’s disease pathology,⁴⁰,⁴¹,⁵⁴–⁵⁶ supporting the promise of D3/FUS treatment as a neuroprotective therapy beyond its effects on amyloid-β levels. Collectively, we interpret our results to support the notion that D3/FUS confers neuroprotection in the presence of established amyloid pathology, and that sustained treatment reduces amyloid-β burden, to positively impact neuronal and cognitive function.

MRIgFUS offers several advantages as a drug delivery modality to achieve NGF-associated bioeffects in the brain. In contrast to current clinical trials that rely on invasive intracranial procedures, MRIgFUS is applied transcranially, thereby minimizing the risk of surgery-related complications. Drug delivery to several brain regions requires multiple injection sites, whereas multiple focal points can be created simultaneously using MRIgFUS, further mitigating technical challenges and improving safety. Furthermore, MRIgFUS-induced BBB permeability, as a proxy for drug delivery, can be visualized by gadolinium leakage at targeted sites immediately after sonication. These features are particularly important in light of recent evidence from NGF clinical trials that report inaccurate targeting and inefficient spread of AAV2-NGF delivery by stereotaxic injection.¹⁴ Emerging evidence also suggests that FUS-mediated BBB permeability may modulate neuronal plasticity and reduce amyloid-β pathology, further supporting its clinical potential.⁴⁰,⁴¹,⁵²,⁵³,⁵⁷,⁵⁸ Relevant to this work, we previously demonstrated that MRIgFUS alone increased NGF levels within 90 min post-sonication, concurrent with D3 delivery in 6-month-old TgCRND8 mice.²¹ Consistent with previous findings, following MRIgFUS alone, we also demonstrate an increase in neural progenitor cell proliferation and the dendritic complexity of newborn neurons.⁴⁰,⁴¹,⁵⁷ yet not newborn neuron survival (Fig. 5). Amyloid-β attenuation following FUS follows a similar trend; the effect size is greater immediately after sonication, but returns to baseline over time.⁵⁸ Overall, these results indicate that the effects of FUS alone are likely transient, and perhaps less pronounced in the hostile microenvironment generated by amyloid-β pathology. Future work will be required to optimize treatment frequency in order to harness the beneficial effects of FUS-induced BBB permeability.

An important safety consideration for clinical translation is whether MRIgFUS BBB modulation itself impacts behavioural and cognitive function in Alzheimer’s disease patients. To date, behavioural effects of MRIgFUS BBB permeability have sparingly addressed in preclinical models with mid-late stage amyloid-β pathology. We demonstrate that MRIgFUS alone does not adversely affect recognition memory in the novel object recognition task (Fig. 1F) or spatial working memory using the spontaneous alternation Y maze test (Fig. 1H), consistent with findings in APP23 transgenic mice with early-stage pathology and no underlying impairment in these tasks.⁵³ We also report comparable spatial learning and memory in the Barnes maze relative to untreated TgCRND8 mice (Fig. 2A–H). Repeated ultrasound treatment improved spatial learning and memory in young APP23 transgenic mice as assessed in the active place avoidance test, but may be insufficient to rescue cognitive deficits as a result of more advanced neuropathology, as seen in 6-month-old TgCRND8 mice in our study. Burgess et al. report improved performance in the reference memory version of the Y maze in older 8-month-old TgCRND8 following MRIgFUS.⁴⁰ However, spatial mapping demands in the active place avoidance test and Y maze are significantly lower than in the Barnes maze, and thus more likely to yield changes in behaviour. Nevertheless, unimpaired performance in the Barnes maze after MRIgFUS treatment underscores the fact that spatial learning and memory is not adversely affected.

We also present data on tasks requiring substantial attentional effort; another cognitive domain severely affected in Alzheimer’s disease patients and modulated by cholinergic tone.⁵⁹ Cognitive flexibility was unaltered by repeated MRIgFUS in the Barnes maze (Fig. 2I–M). Attention deficits in Alzheimer’s disease patients are also associated with impaired performance on activities of daily living.
Figure 8  Locomotor function, anxiety-like behaviour and body weight are not affected following MRIgFUS-mediated delivery of D3. (A) BBB permeability was visualized by the influx of a gadolinium-based MRI contrast agent in sonicated focal spots (red circles). (B) The relative contrast enhancement and (C) sonication pressure were comparable between PBS/FUS and D3/FUS-treated mice, and across repeated sonications. (D) Heat map of general locomotor activity in the open field test. (E) Motor function measured by total distance travelled and (F) average velocity over a 10 min trial was similar across experimental groups. (G) No differences in anxiety-related behaviours were observed across treatment conditions, including time spent in the centre zone and (H) and number of rearing events. (I) Performance in the marble burying test was not impaired; the number of marbles submerged and (J) marbles buried were comparable in all conditions. (K) TgCRND8 mice weighed less than non-Tg mice throughout the study and body weight was not affected by repeated PBS/FUS, D3 or D3/FUS treatment. Scale bar in A = 5 mm. Statistics: (B, C and K) Repeated measures or (E–J) one-way ANOVA with Holm-Sidak post hoc test. Significance: †††P < 0.001. *Comparison of D3/FUS-treated TgCRND8 mice with PBS-treated non-Tg mice (genotype effect). Data represent means ± SEM; (B and C) n = 22–24 per group, (E–K) n = 10–12 per group.
living. Here, there was no difference in nest construction, as a measure of daily living activity, after MRigFUS treatment. MRigFUS did not affect general locomotion and anxiety-related behaviour during the open field test (Fig. 8D–H) and anxiety-like behaviour in the marble burying task (Fig. 8I and J). These results are consistent with other preclinical studies that report increased BBB permeability in the absence of oedema, neuronal damage, and haemorrhage using similar sonication parameters and real-time acoustic feedback control. Repeated MRigFUS-BBB modulation is well-tolerated in Alzheimer’s disease patients, further supporting the safety of this drug delivery modality. Our results show that MRigFUS does not negatively impact cognitive outcomes when applied in a preclinical model with significant cognitive decline as a consequence of Alzheimer’s disease pathogenesis, expanding on the body of evidence that supports the safety of MRigFUS in the Alzheimer’s disease brain.

At this stage, there remain several hurdles before TrkA activation combined with MRigFUS can be realized in therapeutic applications for Alzheimer’s disease. First, current amyloidosis models do not recapitulate the full spectrum of Alzheimer’s disease pathology; the effect of MRigFUS delivery of D3 on other Alzheimer’s disease-related pathologies such as tau pathology and frank neuronal death is still to be determined. Bellucci et al. previously reported BFCN loss in 7-month-old TgCRND8 mice, but this was not observed in our study. Nevertheless, we demonstrate substantial cholinotrophic downregulation, reduced terminal fields, size and phenotype of BFCNs, which impact steady-state cholinergic tone and cognitive decline. Thus, the TgCRND8 model is an Alzheimer’s disease-relevant preclinical model to evaluate cholinergic interventions such as D3/FUS treatment.

Second, clinical trials with NGF-based therapies have reported side effects such as pain and weight loss. Here, systemic delivery of D3 did not reduce body weight over the course of treatment and 1-month follow-up period (Fig. 8K). Moreover, locomotion was unaffected in D3 and D3/FUS-treated mice in the open field test (Fig. 8D–F). These findings suggest that systemic D3 administration is well-tolerated. However, specific pain modality testing was not included in the current study. Future work will be necessary to determine potential sensitivity to pain and establish an effective dose below that threshold, if present.

Third, treatment with a TrkA ligand must take into account the integrity of the individual’s cholinergic system. Preclinical evidence indicates that the effect of TrkA activation on cognition is largely dependent on the brain microenvironment, including age and disease state. While D3 administration improved spatial learning and memory in aged rats and in APP transgenic mice, deficits in spatial memory performance resulted in wild-type, healthy rodents—likewise for NGF. Treatment with NGF or selective TrkA agonists in APP transgenic models without cholinergic degeneration still supported BFCN function and spatial memory, suggesting that under pathological conditions such as cerebral amyloid burden where TrkA signalling is continuously negatively regulated, TrkA stimulation does not negatively impact intact neuronal networks. Personalized therapy with consideration for underlying cholinergic deficits will inform dosing, treatment frequency, and FUS targeting of affected brain regions. Clinical assessment of the BFCNs may be achieved by PET imaging with Trk-specific radiotracers or cholinergic-targeted ligands such as [11C]-MP4A, which binds AChE. In vivo imaging of cortical cholinergic terminals with [11C]-MP4A-PET in MCI patients was found to predict the behavioural response to cholinergic phamacotherapy, supporting its use clinically.

The downregulation of TrkA in cholinergic neurons that under- go selective degeneration in Alzheimer’s disease highlights an important therapeutic role for TrkA-specific agonists. Our findings provide compelling evidence that selective TrkA stimulation, using MRigFUS as a clinically feasible drug delivery platform, can protect against amyloid-β-driven neurodegeneration, including cholinergic deficits and reduced hippocampal neurogenesis, thereby offering a potentially powerful disease-modifying treatment strategy to improve cognitive function in Alzheimer’s disease.

Acknowledgements
We acknowledge Drs Paul Fraser, David Westaway, and Peter St George-Hyslop for supplying breeding pairs of TgCRND8 mice; Kristina Mikloska and Dr. Sheng-Kai Wu for MRigFUS expertise; Shawna Rideout-Gros, Viva Chan and Melissa Theodore for animal care; Hang Yu Lin for illustrations; Dr Christopher Morrone for helpful consultation on behavioural testing and analyses.

Funding
This work was supported by the Canadian Institutes of Health Research (FNR-93603 to I.A., FDN-154272 to K.H.), Weston Brain Institute (TR130117 to I.A.), National Institute of Biomedical Imaging and Bioengineering (RO1-EB003268 to K.H.), Canadian Consortium on Neurodegeneration in Aging (to H.U.S.), FDC Foundation, WB Family Foundation, Gerald and Carla Connor. This research was undertaken, in part, thanks to funding from the Canada Research Chairs Program (I.A., Tier 1 CRC in Brain Repair and Regeneration) and the Temerty Chair in Focused Ultrasound Research at Sunnybrook Health Sciences Centre. K.K. was awarded a Frederick Banting and Charles Best Canada Graduate Scholarship (GSD-152271). R.H.K. received a Postdoctoral Fellowship from the Alzheimer Society of Canada (19-10).

Competing interests
K.H. is co-founder of FUS Instruments and inventor on several patents related to BBB modulation using ultrasound.

Supplementary material
Supplementary material is available at Brain online.

References
1. Chen X-Q, Mobley WC. Exploring the pathogenesis of Alzheimer disease in basal forebrain cholinergic neurons: Converging insights from alternative hypotheses. Front Neurosci. 2019;13:446.
2. Dubois B, Chupin M, Hampel H, et al. Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer’s disease. Alzheimers Dement. 2015;11:1041–1049.
3. Cavedo E, Dubois B, Colliot O, et al. Reduced regional cortical thickness rate of change in donepezil-treated subjects with suspected prodromal Alzheimer’s disease. J Clin Psychiatry. 2016;77: e1631–e1638.
4. Cavedo E, Grothe MJ, Colliot O, et al. Reduced basal forebrain atrophy progression in a randomized donepezil trial in prodromal Alzheimer’s disease. Sci Rep. 2017;7:11706.
5. Tusznyski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer’s disease. Nat Med. 2005;11:551–555.

6. Rafii MS, Tuszynski MH, Thomas RG, et al. Adeno-associated viral vector (Serotype 2)-nerve growth factor for patients with Alzheimer disease: A randomized clinical trial. JAMA Neurol. 2018;75:834–841.

7. Karami A, Eyjolfsdottir H, Vijayaraghavan S, et al. Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer’s disease. Alzheimers Dement. 2015;11:1316–1328.

8. Maliartchouk S, Feng Y, Ivanisevic L, et al. Encapsulated cell biodelivery of nerve growth factor to the basal forebrain in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2012;33:18–28.

9. Eyjolfsdottir H, Eyjolfsdottir M, Linderoth B, Lind G, et al. Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer disease patients: application of a second-generation encapsulated cell biodelivery device. Alzheimers Res Ther. 2016;8:30.

10. Ferreira D, Westman E, Eyjolfsdottir H, et al. Brain changes in Alzheimer patients with implanted encapsulated cells releasing nerve growth factor. J Alzheimers Dis. 2015;43:1095–1072.

11. Cuello AC, Pentz R, Hall H. The brain NGF metabolic pathway in health and in Alzheimer’s pathology. Front Neurol. 2015;6:62.

12. Capsoni S, Malerba F, Carucci NM, et al. The chemokine CXCL12 mediates the anti-amyloidogenic action of painless human nerve growth factor. Brain. 2017;140:201–217.

13. Honig LS. Gene therapy in Alzheimer disease—it may be feasible, but will it be beneficial? JAMA Neurol. 2018;75:791–793.

14. Castle MJ, Baltanás FC, Kovaci I, Nagahara AH, Barba D, Tusznyski MH. Postmortem analysis in a clinical trial of AAV2-NGF gene therapy for Alzheimer’s disease identifies a need for improved vector delivery. Hum Gene Ther. 2020;31:415–422.

15. Wahlberg LU, Lind G, Almqvist MP, et al. Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery. J Neurosurg. 2012;117:340–347.

16. Khima K, Aubert I. The therapeutic potential of nerve growth factor combined with blood-brain barrier modulation by focused ultrasound for neurodegenerative disorders. Neural Regen Res. 2021;16:1783–1785.

17. Ginsberg SD, Che S, Wuu J, Counts SE, Mufson EJ. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer’s disease. J Neurochem. 2006;97:475–487.

18. Maliarzhouk S, Feng Y, Ivanisevic L, et al. A designed peptidomimetic agonistic ligand of TrkA nerve growth factor receptors. Mol Pharmacol. 2000;57:385–391.

19. Bruno MA, Clarke PBS, Seltzer A, et al. Long-lasting rescue of age-associated deficits in cognition and the CNS cholinergic phenotype by a partial agonist peptidomimetic ligand of TrkA. J Neurosci. 2004;24:8009–8018.

20. Abouikassim T, Tong X-K, Tse YC, et al. Ligand-dependent TrkA activity in brain differentially affects spatial learning and long-term memory. Mol Pharmacol. 2011;80:498–508.

21. Khima K, Markham-Coults K, Nedev H, et al. Focused ultrasound delivery of a selective TrkA agonist rescues cholinergic function in a mouse model of Alzheimer’s disease. Sci Adv. 2020;6:eaax6646.

22. Khima K, McMahon D, Ntiri E, Goubran M, Hynynen K, Aubert I. Intravenous and non-invasive drug delivery to the mouse basal forebrain using MRI-guided focused ultrasound. Bio Protoc. 2021;11:e4056.

23. Chishti MA, Yang DS, Janus C, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem. 2001;276:21562–21570.

24. Nagy PM, Aubert I. Overexpression of the vesicular acetylcholine transporter increased acetylcholine release in the hippocampus. Neuroscience. 2012;218:1–11.

25. Thal DR, Rüb U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of Alzheimer’s disease. Neurology. 2002;58:1791–800.

26. Adalbert R, Nagradi A, Babetto E, et al. Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies. Brain. 2009;132:402–416.

27. Kimura R, MacTavish D, Yang J, Westaway D, Jhamandas JH. Beta amyloid-induced depression of hippocampal long-term potentiation is mediated through the amylin receptor. J Neurosci. 2012;32:17401–17406.

28. Hamm V, Héraud C, Bott JB, et al. Differential contribution of APP metabolites to early cognitive deficits in a TgCRND8 mouse model of Alzheimer’s disease. Sci Adv. 2017;3:e1601068.

29. Brautigam H, Steele JW, Westaway D, et al. The isotropic fractionator provides evidence for differential loss of hippocampal neurons in two mouse models of Alzheimer’s disease. Mol Neurodegener. 2012;7:58.

30. Steele JW, Brautigam H, Short JA, et al. Early fear memory defects are associated with altered synaptic plasticity and molecular architecture in the TgCRND8 Alzheimer’s disease mouse model. J Comp Neurol. 2014;522:2319–2335.

31. Bellucci A, Luccarini I, Scal C, et al. Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice. Neurobiol Dis. 2006;23:260–272.

32. McKeever PM, Kim T, Hesketh AR, et al. Cholinergic neuron gene expression differences captured by translational profiling in a mouse model of Alzheimer’s disease. Neurobiol Aging. 2017;57:104–119.

33. Proulx É, Fraser P, McLaurin J, Lambe EK. Impaired cholinergic excitation of prefrontal attention circuitry in the TgCRND8 model of Alzheimer’s disease. J Neurosci. 2015;35:12779–12791.

34. Proulx É, Power SK, Oliver DK, Sargin D, McLaurin J, Lambe EK. Apatin improves prefrontal nicotinic impairment in mouse model of Alzheimer’s disease. Cereb Cortex. 2020;30:563–574.

35. Maliszewska-Cyna E, Khima K, Aubert I. A comparative study evaluating the impact of physical exercise on disease progression in a mouse model of Alzheimer’s disease. J Alzheimers Dis. 2016;53:243–257.

36. Herring A, Ambée O, Tjom M, et al. Environmental enrichment enhances cellular plasticity in transgenic mice with Alzheimer-like pathology. Exp Neurol. 2009;216:184–192.

37. Ito Y, Nochi R, Kuribayashi H, Saito Y, Hisatsune T. Cholinergic activation of hippocampal neural stem cells in aged dentate gyrus. Hippocampus. 2011;21:446–459.

38. Christian KM, Ming G-L, Song H. Adult neurogenesis and the dentate gyrus: Predicting function from form. Behav Brain Res. 2020;379:112346.

39. Morrone CD, Thomason LAM, Brown ME, Aubert I, McLaurin J. Effects of neurotrophic support and amyloid-targeted combined therapy on adult hippocampal neurogenesis in a transgenic model of Alzheimer’s disease. PLoS One. 2016;11:e0165393.

40. Burgess A, Dubey S, Yeung S, et al. Alzheimer disease in a mouse model: MR imaging-guided focused ultrasound targeted to the hippocampus opens the blood-brain barrier and improves pathologic abnormalities and behaviour. Radiology. 2014;273:736–745.
41. Shin J, Kong C, Lee J, et al. Focused ultrasound-induced blood-brain barrier opening improves adult hippocampal neurogenesis and cognitive function in a cholinergic degeneration dementia rat model. *Alzheimers Res Ther*. 2019;11:110.

42. Llorens-Martín M, Jurado-Arjona J, Fuster-Matanzo A, Hernández F, Rábano A, Ávila J. Peripherally triggered and microbubbles ultrasound and microglial activation in response to ibuprofen. *Transl Psychiatry*. 2014;4:e463.

43. Petty BG, Cornblath DR, Adornato BT, et al. Cholinergic modulation of amyloid precursor protein restores memory in an Alzheimer dementia rat model. *Exp Neurol*. 2018;309:51–67.

44. Markowska AL, Koliatsos VE, Breckler SJ, Price DL, Olton DS. Failed retrograde transport of NGF in a mouse model of Down’s syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. *Proc Natl Acad Sci USA*. 2001;98:1395–1400.

45. Lipsman N, Meng Y, Bethune AJ, et al. Human nerve growth factor improves spatial memory in aged but not in young rats. *J Neurosci*. 1997;17:2543–2550.

46. Frick KM, Price DL, Koliatos VE, Markowska AL. The effects of NGF on spatial memory in aged rats persist after discontinuation of treatment. *J Neurosci*. 1997;17:2543–2550.

47. Cooper JD, Salehi A, Delcroix JD, et al. Noninvasive hippocampal blood–brain barrier opening in Alzheimer’s disease with focused ultrasound. *Proc Natl Acad Sci USA*. 2020;117:9180–9182.

48. Jönsson ME, Nordberg A, Amberla K, et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer’s disease. *Dement Geriatr Cogn Disord*. 1998;9:246–257.

49. Joseph-Hernandez S, Pirvulescu I, Maira M, et al. Pharmacological interrogation of TrkA-mediated mechanisms in hippocampal-dependent memory consolidation. *PLoS One*. 2019;14:e0218036.

50. Markowska AL, Koliatos VE, Breckler SJ, Price DL, Olton DS. Human nerve growth factor improves spatial memory in aged rats but not in young rats. *J Neurosci*. 1994;14:4815–4824.

51. Richter N, Beckers N, Onur OA, et al. Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer’s disease. *Brain*. 2018;141:903–915.